Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
30 participants
INTERVENTIONAL
2022-09-30
2023-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Iris Tissue in Primary Congenital Glaucoma
NCT04079725
Electron Microscopic Examination of Iris Tissue in Buphthalmos
NCT07034651
Histopathological Examination of Iris Tissue in Buphthalmos
NCT04011878
Optical Coherence Tomography of the Irido-Corneal Angle Before and After Goniotomy and Trabeculotomy in Primary Congenital Glaucoma
NCT07012252
Patterns of Glaucoma in Glaucoma Subspecialty Clinics in Egypt and India in the Year 2018
NCT03491735
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Estimation of vascular endothelial growth factor (VEGF) in iris tissue specimen taking from ocular trauma or congenital cataract used as control.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
VEGF in iris tissue in primary congenital glaucoma
Estimation of VEGF grade in iris tissue in primary congenital glaucoma through Immunohistochemistry
Immunohistochemistry analysis
Estimation of VEGF through Immunohistochemistry
VEGF in iris tissue from ocular trauma or congenital cataract
Estimation of VEGF grade in iris tissue from ocular trauma or congenital cataract through Immunohistochemistry
Immunohistochemistry analysis
Estimation of VEGF through Immunohistochemistry
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Immunohistochemistry analysis
Estimation of VEGF through Immunohistochemistry
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Secondary glaucoma.
* Glaucoma associated with other congenital anomalies.
1 Day
1 Year
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hassan Lotfy Fahmy
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hassan Lotfy Fahmy
Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hassan Lotfy
Asyut, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2323300
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.